Cancer treatment
The invention relates generally to the treatment of cancer. One embodiment of the invention provides a method of treating cancer in an individual, the method comprising: administering to the individual an effective amount of trichostatin A (TSA).
1. In method of treating a patient diagnosed with cancer with trichostatin A (TSA), the improvement comprising:
selecting for treatment a patient determined to have both increased histone deacetylase (HDAC) activity and aurora kinase A (AURKA) expression, wherein the cancer is selected from a group consisting of breast cancer, gastric cancer, colon cancer, bladder cancer, pancreatic cancer, ovarian cancer, prostate cancer, and lung cancer.
2. The improvement of claim 1 , wherein the treating includes administering TSA to the selected patient in an amount sufficient to decrease an AURKA level in the patient.
3. The improvement of claim 1 , wherein the treating includes administering TSA to the selected patient in an amount sufficient to inhibit HDAC activity and decrease an AURKA level in the patient.
4. The improvement of claim 1 , wherein the treating includes administering TSA to the selected patient in between about 0.1 mg/kg/day and about 10 mg/kg/day.
5. The improvement of claim 4 , wherein the treating includes administering TSA to the selected patient in between about 0.5 mg/kg/day and about 5 mg/kg/day.
6. The improvement of claim 5 , wherein the treating includes administering TSA as the only AURKA inhibitor administered to the patient.
7. The improvement of claim 1 , wherein the treating includes orally administering TSA.
8. The improvement of claim 1 , wherein the treating includes intravenously administering TSA.
9. The improvement of claim 1 , wherein the improvement further comprises:
determining, from a tumor sample obtained from the patient's body, a level of AURKA expression.
10. The improvement of claim 1 , wherein the cancer is breast cancer.